JOHNSON & JOHNSON | 2013 | FY | 3

 
 
Sales to Customers
(Dollars in Millions)
 
2013
 
2012
 
2011
Consumer —
 
 
 
 
 
 
United States
 
$
5,162

 
5,046

 
5,151

International
 
9,535

 
9,401

 
9,732

Total
 
14,697

 
14,447

 
14,883

Pharmaceutical —
 
 
 
 
 
 
United States
 
13,948

 
12,421

 
12,386

International
 
14,177

 
12,930

 
11,982

Total
 
28,125

 
25,351

 
24,368

Medical Devices and Diagnostics —
 
 
 
 
 
 
United States
 
12,800

 
12,363

 
11,371

International
 
15,690

 
15,063

 
14,408

Total
 
28,490

 
27,426

 
25,779

Worldwide total
 
$
71,312

 
67,224

 
65,030


 
 
Pre-Tax Profit
 
Identifiable Assets
(Dollars in Millions)
 
2013 (3)
 
2012 (4)
 
2011 (5)
 
2013
 
2012
 
2011
Consumer
 
$
1,973

 
1,693

 
2,096

 
$
23,711

 
24,131

 
24,210

Pharmaceutical
 
9,178

 
6,075

 
6,406

 
23,783

 
23,219

 
23,747

Medical Devices and Diagnostics
 
5,261

 
7,187

 
5,263

 
44,585

 
42,926

 
23,609

Total
 
16,412

 
14,955

 
13,765

 
92,079

 
90,276

 
71,566

Less: Expense not allocated to segments (1)
 
941

 
1,180

 
1,404

 
 
 
 
 
 
General corporate (2)
 
 
 
 
 
 
 
40,604

 
31,071

 
42,078

Worldwide total
 
$
15,471

 
13,775

 
12,361

 
$
132,683

 
121,347

 
113,644


 
 
Additions to Property,
Plant & Equipment
 
Depreciation and
Amortization
(Dollars in Millions)
 
2013
 
2012
 
2011
 
2013
 
2012
 
2011
Consumer
 
$
533

 
468

 
670

 
$
539

 
575

 
631

Pharmaceutical
 
856

 
737

 
729

 
1,075

 
1,010

 
958

Medical Devices and Diagnostics
 
1,724

 
1,230

 
1,095

 
2,224

 
1,857

 
1,331

Segments total
 
3,113

 
2,435

 
2,494

 
3,838

 
3,442

 
2,920

General corporate
 
482

 
499

 
399

 
266

 
224

 
238

Worldwide total
 
$
3,595

 
2,934

 
2,893

 
$
4,104

 
3,666

 
3,158

us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock